New hope for advanced kidney cancer: experimental drug enters early trial
Disease control
Not yet recruiting
This early-stage study tests a new drug called UCL70805F in 21 people with advanced clear cell kidney cancer that has not responded to standard treatments. The main goals are to check the drug's safety and see if it can shrink tumors. Participants must have a specific marker (CD7…
Phase: PHASE1 • Sponsor: UTC Therapeutics Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC